| 4.62 0 (0%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.04 |
1-year : | 8.38 |
| Resists | First : | 6.03 |
Second : | 7.17 |
| Pivot price | 5.61 |
|||
| Supports | First : | 4.17 |
Second : | 3.47 |
| MAs | MA(5) : | 4.92 |
MA(20) : | 5.73 |
| MA(100) : | 5.35 |
MA(250) : | 5.93 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 6.6  |
D(3) : | 5.5 |
| RSI | RSI(14): 37.5 | |||
| 52-week | High : | 12.35 | Low : | 3.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RXRX ] has closed above bottom band by 7.2%. Bollinger Bands are 83.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.64 - 4.67 | 4.67 - 4.7 |
| Low: | 4.11 - 4.15 | 4.15 - 4.18 |
| Close: | 4.56 - 4.62 | 4.62 - 4.68 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Fri, 07 Nov 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - simplywall.st
Fri, 07 Nov 2025
Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships? - Yahoo Finance
Fri, 07 Nov 2025
Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss - Quiver Quantitative
Fri, 07 Nov 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 06 Nov 2025
Will RXRX Recover From Earnings Miss? - StocksToTrade
Wed, 05 Nov 2025
Recursion Pharmaceuticals (RXRX): Five-Year Loss Acceleration Challenges Bulls Despite 30.1% Revenue Growth Forecast - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 430 (M) |
| Shares Float | 416 (M) |
| Held by Insiders | 4.7 (%) |
| Held by Institutions | 69.8 (%) |
| Shares Short | 126,350 (K) |
| Shares Short P.Month | 132,040 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.11 |
| Profit Margin | 0 % |
| Operating Margin | -916.8 % |
| Return on Assets (ttm) | -39.1 % |
| Return on Equity (ttm) | -86.4 % |
| Qtrly Rev. Growth | 33.2 % |
| Gross Profit (p.s.) | -1.01 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -1.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -383 (M) |
| Levered Free Cash Flow | -186 (M) |
| PE Ratio | -2.56 |
| PEG Ratio | 0 |
| Price to Book value | 2.17 |
| Price to Sales | 30.73 |
| Price to Cash Flow | -5.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|